MP03-12 STAGING ADVANCED AND METASTATIC CLEAR CELL RENAL CELL CARCINOMA WITH 68 GALLIUM PSMA PET FOR TREATMENT PLANNING

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I1 Apr 2016MP03-12 STAGING ADVANCED AND METASTATIC CLEAR CELL RENAL CELL CARCINOMA WITH 68 GALLIUM PSMA PET FOR TREATMENT PLANNING Handoo Rhee, Chui Ming Tham, Paul Thomas, John Blazak, Hema Samaratunga, Keng Lim Ng, Glenda Gobe, Ian Vela, and Simon Wood Handoo RheeHandoo Rhee More articles by this author , Chui Ming ThamChui Ming Tham More articles by this author , Paul ThomasPaul Thomas More articles by this author , John BlazakJohn Blazak More articles by this author , Hema SamaratungaHema Samaratunga More articles by this author , Keng Lim NgKeng Lim Ng More articles by this author , Glenda GobeGlenda Gobe More articles by this author , Ian VelaIan Vela More articles by this author , and Simon WoodSimon Wood More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1905AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Positron emission tomography (PET) using novel inhibitors of prostate specific membrane antigen (PSMA) has recently been used to detect localized and metastatic prostate cancer lesions with high sensitivity and specificity in comparison to standard imaging. PSMA is also known to be highly expressed in the neovasculature of clear cell renal cell carcinoma. In this study, we explore the PSMA expression in renal cell carcinoma foci to help stage patients with advanced and metastatic clear cell renal cell carcinoma. METHODS Sixteen patients with advanced renal cell carcinoma was imaged using 68 Gallium PSMA PET in addition to standard imaging such as computer tomography (CT), ultrasound, bone scan or magnetic resonance imaging. Eleven patients had primary renal tumour with local invasion, inferior vena cava extension, whilst four patients were known to have metastatic disease after treatment of primary renal tumour. In 12 patients, histopathological tissue was available for correlation. RESULTS In all 16 patients, PET avid lesions were identified in primary and putative metastatic lesions. Avidity and SUVmax was particularly elevated in patients with metastatic lesions and vascular extension into renal vein, vena cava, and lumbar veins. In all patients, CT images were available for direct comparison. Overall, a significantly larger number of lesions were identified using PET, resulting in change of treatment approaches for six patients (37.5%, n=6/16) (surgical margins or additional therapy such as stereotactic radiotherapy or targeted therapy). On histopathological correlation, 100% of PET avid lesions (n=24) were positive for renal cell carcinoma. CONCLUSIONS PSMA avidity in the neovasculature of clear cell renal cell carcinoma foci can be used as an opportunity to stage patients with metastatic or advanced renal cell carcinoma, which may result in change of surgical margins or further treatment. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e23 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Handoo Rhee More articles by this author Chui Ming Tham More articles by this author Paul Thomas More articles by this author John Blazak More articles by this author Hema Samaratunga More articles by this author Keng Lim Ng More articles by this author Glenda Gobe More articles by this author Ian Vela More articles by this author Simon Wood More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...